Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsShortsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Cindy Chmielewski

Advertisement

Articles by Cindy Chmielewski

Myeloma Survivor Shares Insights on Adherence to Oral Anticancer Medications

ByCindy Chmielewski
November 23rd 2016

While many oral therapies are used to treat multiple myeloma, nonadherence to oral anticancer agents continues to be a challenge.

Advertisement

Latest Updated Articles

  • Myeloma Survivor Shares Insights on Adherence to Oral Anticancer Medications
    Myeloma Survivor Shares Insights on Adherence to Oral Anticancer Medications

    November 23rd 2016



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer

2

Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights

3

GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival

4

FDA Approves Oral Nilotinib Tablets for Ph+ CML

5

Pembrolizumab Improves 7-Year OS in Early-Stage TNBC: KEYNOTE-522 Final Data

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us